Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients from 1 month to less than 4 years of age~* Pediatric patients diagnosed with refractory partial onset seizures, on a stable regimen of one to two other anti-epileptic drugs and at least 2 partial onset seizures per week in the two weeks prior to screening~* Patients must have two partial onset seizures (with corresponding clinical event) during the 48-hour video EEG at screening~Exclusion Criteria:~* A ketogenic diet~* Previous exposure to levetiracetam~* Seizures too close together to count accurately~* Treatable seizure etiology~* Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease~* Diagnosis of a terminal illness

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
- Levetiractem (Type: EXPERIMENTAL): 10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).